매출 +43% 고성장, 영업이익률 개선(+15.8%p). 11/5 실적 발표 예정.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provide
2026-10-21 기준 · 출처: SEC EDGAR, FINRA, yfinance · 정보 제공용이며 투자 권유가 아닙니다